CHICAGO, IL--(Marketwired - Jun 6, 2016) - Predicine, Inc. and CloudHealth Genomics Ltd announced today at the American Society of Clinical Oncology (ASCO) 2016 meeting, to offer Predicine's liquid biopsy tests to patients with lung (PrediSeq-Lung) or prostate (PrediSeq-Prostate) cancer in China.

Lung cancer is the number one cause of mortality in China. Prostate cancer on the other hand is the fastest growing cancer type in China and the most common and second leading cause of cancer death in the western world. Earlier this year, Dr. Winston Patrick Kuo, President of Predicine, introduced their PrediSeq-Lung liquid biopsy test at the 23rd International Molecular Medicine Tri-Conference, which took place in San Francisco. A month later, Predicine presented data introducing PrediSeq-Prostate, the world's first liquid biospy NGS test for precision medicine in prostate cancer, at the American Association of Cancer Research (AACR) annual meeting in New Orleans. Both tests are based on Predicine's patented NGS technology, detecting genetic alterations (mutations, copy number, indel, rearrgangement and splice variants) in circulation.

"We are committed to developing the first- and best-in-class non-invasive NGS-based cancer tests to enable personalized cancer care and global drug development," said Dr. Shidong Jia, Founder and CEO of Predicine. "We are glad to work with industry leaders like CloudHealth so as to serve more patients in China in a timely manner," Dr. Jia added. Predicine plans to launch additional tests for major cancer types in China later this year.

The tests have been rigorously validated and are now being adopted by leading pharmaceutical companies in the US and China. "The recognition of PrediSeq cancer tests by top-notch pharmaceutical companies is a testament of the science and quality behind Predicine," Dr. Jason Jin, CEO and Co-founder of CloudHealth, said in a statement. "We are excited to move forward with Predicine to offer cancer patients and drug development companies instant access to the state-of-the-art liquid biopsy technology," Dr. Jin added.

About Predicine

Predicine Holdings Ltd is an international precision medicine organization that is committed to developing innovative diagnostics, therapeutics and big data in cancer and other serious diseases. Predicine is formed by a group of industry veterans with leadership experience and domain expertise in precision oncology, liquid biopsy, cancer diagnostics, next-generation sequencing, biomarker development, drug discovery, clinical trial, bioinformatics and cloud computing. Following the principle of science-driven and patient-first spirit, Predicine develops innovative non-invasive precision diagnostic products in cancer and other serious diseases, provides an integrated "one-stop-shop" biomarker service platform, and conducts big data analyses to enable precision medicine in personalized cancer care and global drug development. The company operates in Hayward, California USA and Shanghai, China. Visit to learn more.

About CloudHealth

CloudHealth Genomics Ltd based in Shanghai, China, is a high-tech company and pioneer in China on genomics sequencing for preventive medicine and precision medicine. CloudHealth owns the whole genome sequencing platform of HiSeq X10, Clinic Genetic Test Lab, High-End Clinic Center, Big Data Center, Genomics Research Institute, Life Center, Medical Doctor's Alliance, and Academician Workstation. CloudHealth has an international team of nearly 100 scientists in life science and bioinformatics fields led by well-known world experts. CloudHealth has established an integrated big health and precision medicine service chain including whole genome sequencing, genetic testing, premium examination, health counseling, health management and precision medicine. Visit to learn more.

Contact Information:

Winston Patrick Kuo, DDS, DMSc
Predicine, Inc.
650-300-2188 (USA)

Jason Gang Jin, MD, PhD
CEO, Co-Founder
CloudHealth Genomics Ltd.